Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 1997

View Archived Issues

Company Profile: Synaptic

Merck & Co. reports new product candidate and pipeline overview

Abelcet continues to demonstrate effectiveness

New data on PDL's SMART M195 antibody reported

Alfacell: Q1 1998 highlights

BTG: Six-month 1997 highlights

Immune Response recommended to continue Remune phase III trial

LXR discovers new apoptosis-related proteins and genes

Tokyo Tanabe moves new oxytocin antagonist to clinic

Daiichi files for approval of ebselen

Kyowa Hakko prepares new, water-soluble indole for osteoporosis

Hokuriku describes new calcium agonist derived from intracellular calcium antagonist

Diphosphonate antiarthritic agent developed at Toray

Site-directed, sustained-release delivery system for estradiol in development at Fujisawa

Preclinical profile of optically active triazole antifungal agent presented by Takeda

TheraTech and P&G to codevelop hormone replacement patches

Effects of BO-653 and related compounds on various active oxygen species

Alza and Warner-Lambert sign distribution agreement for nasal decongestant OTC

Phase I trial of oral TBC-11251 successfully completed

EU approves ciclosporin bulk substance

Ligand reports positive results from U.S. pivotal phase III trial of Panretin Gel

Alferon N Injection completes phase III in HIV

MedImmune and SKB establish worldwide alliance for HPV vaccines

Cel-Sci expands Multikine trial

First FDA approval for humanized MAb: Zenapax for renal transplant patients

Genzyme Transgenics' idiotypic vaccines show promise in clinical trials

FDA approves URSO for PBC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...